<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193879</url>
  </required_header>
  <id_info>
    <org_study_id>2015CB553402</org_study_id>
    <nct_id>NCT03193879</nct_id>
  </id_info>
  <brief_title>Effects of Particulate Matter on the Pulmonary Function and Acute Exacerbation of COPD and Asthma</brief_title>
  <official_title>Effects of Particulate Matter on the Lung Function and Acute Exacerbation of COPD and Asthma Patients--A Multi-center Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xinjiang Autonomous Region People 's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cangzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu sixth People 's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengde Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Fengtai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Medical College, Ningbo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changzhi Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Boai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhu Hospital of Chinese Traditional Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Jingzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Zhongshan Asthma Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rizhao Hospital of Chinese Traditional Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>3201 Hospital in Hanzhong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu Fifth People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People 's Hospital of Changsha</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Jiangjin Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the Affiliated hospital of Guilin medical university, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangxi People 's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese People 's Liberation Army Navy Anqing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Inner Mongolia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yancheng Dafeng People 's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ShuGuang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of the Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taizhou Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People 's Hospital of Kunming</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People 's Hospital of Yunnan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pingxiang People 's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northern Jiangsu People 's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Economic Hospital of Xinjiang Uygur Autonomous Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Particulate matter(PM) exposure has been shown to increase the morbidity and mobility of a&#xD;
      variety of respiratory diseases, including COPD and asthma. This study focus on the effects&#xD;
      of PM on the pulmonary function and acute exacerbation of COPD and asthma patients in China,&#xD;
      where PM exposure is much heavier than the United States and European countries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Particulate matter(PM) exposure has been shown to increase the morbidity and mobility of a&#xD;
      variety of respiratory diseases, including COPD and asthma. This study focus on the effects&#xD;
      of PM on the pulmonary function and acute exacerbation of COPD and asthma patients in China,&#xD;
      where PM exposure is much heavier than the United States and European countries. This study&#xD;
      is an observational study which lasts 3 years. Primary outcome measures:Change in spirometry&#xD;
      (FEV1) of COPD, asthma patients and healthy volunteers in response to different exposure&#xD;
      doses of PM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">September 2021</completion_date>
  <primary_completion_date type="Actual">September 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Change in spirometry (FEV1) of COPD, asthma patients and healthy volunteers in response to different exposure doses of PM.</measure>
    <time_frame>2 years</time_frame>
    <description>Spirometry will be assessed at baseline and through study completion, an average of 2 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in morbidity of acute exacerbation in COPD and asthma patients in response to different exposure doses of PM.</measure>
    <time_frame>2 years</time_frame>
    <description>Patients will be followed up through study completion, an average of 2 years.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">505</enrollment>
  <condition>Pulmonary Function</condition>
  <arm_group>
    <arm_group_label>COPD group</arm_group_label>
    <description>COPD patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthma group</arm_group_label>
    <description>Asthma patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Health group</arm_group_label>
    <description>Healthy volunteers</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biological specimens are preserved in serum, plasma, and leukocytes&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Clinic-based population&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. COPD patients: clinical manifestation of COPD; post bronchodilator FEV1/FVC&lt;0.70.&#xD;
&#xD;
          2. Asthma patients: clinical manifestation of asthma; recurrent dyspnea; with or without&#xD;
             wheezing; relief spontaneously or after using bronchodilators; FEV1/FVC&lt;0.70,with&#xD;
             positive bronchial reversible test.&#xD;
&#xD;
          3. Asthma combined with COPD (ACOS) patients: patients with ACOS are included in asthma&#xD;
             group.&#xD;
&#xD;
          4. Healthy volunteers: No smoking history, or have quit smoking at least 5 years. Chest&#xD;
             X-ray show no abnormality.&#xD;
&#xD;
          5. Information consent form should be signed before entering the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The latest severe acute attack occurred within 4 weeks:&#xD;
&#xD;
               1. Severe acute attack: status asthmaticus or acute exacerbation of COPD leading to&#xD;
                  consultation, emergency treatment，hospitalization, or glucocorticoid&#xD;
                  treatment（oral/i.v).&#xD;
&#xD;
               2. Controllable non-hospitalized acute attack without glucocorticoid&#xD;
                  treatment(oral/i.v). COPD attack lasting less than 48h or asthma attack lasting&#xD;
                  less than 24h are not excluded.&#xD;
&#xD;
          2. Any history of acute/chronic respiratory diseases other than asthma and COPD,&#xD;
             including lung cancer and pulmonary infection.&#xD;
&#xD;
          3. Plasma ALT or AST greater than 2 times of the upper normal limit; plasma Creatinine&#xD;
             greater than 1.5 times of the upper normal limit.&#xD;
&#xD;
          4. Left heart insufficiency, or malignant arrhythmia.&#xD;
&#xD;
          5. HIV positive.&#xD;
&#xD;
          6. Acute cerebrovascular events within 3 months, including apoplexy, transient cerebral&#xD;
             ischemia and acute coronary syndrome.&#xD;
&#xD;
          7. Uncured malignant tumors.&#xD;
&#xD;
          8. Addicted to drug or alcohol, or any history of psychiatric disorders.&#xD;
&#xD;
          9. Breastfeeding, pregnancy or planning to be pregnant.&#xD;
&#xD;
         10. Estimated lifetime less than 2 years due to underlying diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary function</keyword>
  <keyword>Particulate matter</keyword>
  <keyword>COPD</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

